We serve Chemical Name:N-methyl-1-(2-thiomorpholin-4-ylpyridin-4-yl)methanamine CAS:906352-66-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N-methyl-1-(2-thiomorpholin-4-ylpyridin-4-yl)methanamine
CAS.NO:906352-66-7
Synonyms:N-methyl-1-(2-thiomorpholin-4-ylpyridin-4-yl)methanamine
Molecular Formula:C11H17N3S
Molecular Weight:223.33800
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:140-150/0.3mm
Density:1.139g/cm3
Index of Refraction:1.586
PSA:53.46000
Exact Mass:223.11400
LogP:1.81010
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-methyl-1-(2-thiomorpholin-4-ylpyridin-4-yl)methanamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-methyl-1-(2-thiomorpholin-4-ylpyridin-4-yl)methanamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-methyl-1-(2-thiomorpholin-4-ylpyridin-4-yl)methanamine Use and application,N-methyl-1-(2-thiomorpholin-4-ylpyridin-4-yl)methanamine technical grade,usp/ep/jp grade.
Related News: Inceptua has global operations with local offices across Europe, USA, and Asia N-methyl-1-(2-thiomorpholin-4-ylpyridin-4-yl)methanamine manufacturer This also includes its anti-tau pipeline, with the FDA’s approval having “implications for AD programmes targeting Tau,” according to Jefferies. N-methyl-1-(2-thiomorpholin-4-ylpyridin-4-yl)methanamine supplier Retrogenix��s proprietary cell microarray technology provides a fast, accurate and effective solution for determining the primary target and secondary target (off-target) activities of antibodies, proteins, cell therapies, small molecules and viruses. N-methyl-1-(2-thiomorpholin-4-ylpyridin-4-yl)methanamine vendor Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). N-methyl-1-(2-thiomorpholin-4-ylpyridin-4-yl)methanamine factory During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology.
